|
nasdaq:ljpc
|
26006
|
Apr 14th, 2024 12:00AM
|
La Jolla Pharmaceutical Company
|
25K
|
91.00
|
Open
|
|
Apr 13th, 2024 11:17PM
|
Apr 14th, 2024 11:16AM
|
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
|
Open
|
|
Open
|
201 Jones Rd, Suite 400
|
Waltham
|
MA
|
US
|
02451
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
148626
|
Apr 14th, 2024 12:00AM
|
Tetraphase Pharmaceuticals
|
3.9K
|
16.00
|
Open
|
|
Apr 13th, 2024 11:17PM
|
Apr 14th, 2024 11:16AM
|
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions.
Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
|
Open
|
Antibiotics, Gram-negative antibiotics, multidrug-resistant infections, antibiotic resistance, biopharmaceutical, and bacterial resistance
|
Open
|
480 Arsenal St
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
26006
|
Apr 13th, 2024 12:00AM
|
La Jolla Pharmaceutical Company
|
25K
|
91.00
|
Open
|
|
Apr 12th, 2024 11:09PM
|
Apr 13th, 2024 11:43AM
|
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
|
Open
|
|
Open
|
201 Jones Rd, Suite 400
|
Waltham
|
MA
|
US
|
02451
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
148626
|
Apr 13th, 2024 12:00AM
|
Tetraphase Pharmaceuticals
|
3.9K
|
16.00
|
Open
|
|
Apr 12th, 2024 11:09PM
|
Apr 13th, 2024 11:43AM
|
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions.
Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
|
Open
|
Antibiotics, Gram-negative antibiotics, multidrug-resistant infections, antibiotic resistance, biopharmaceutical, and bacterial resistance
|
Open
|
480 Arsenal St
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
148626
|
Apr 12th, 2024 12:00AM
|
Tetraphase Pharmaceuticals
|
3.9K
|
16.00
|
Open
|
|
Apr 11th, 2024 11:14PM
|
Apr 12th, 2024 08:38AM
|
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions.
Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
|
Open
|
Antibiotics, Gram-negative antibiotics, multidrug-resistant infections, antibiotic resistance, biopharmaceutical, and bacterial resistance
|
Open
|
480 Arsenal St
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
26006
|
Apr 12th, 2024 12:00AM
|
La Jolla Pharmaceutical Company
|
25K
|
92.00
|
Open
|
|
Apr 11th, 2024 11:14PM
|
Apr 12th, 2024 08:38AM
|
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
|
Open
|
|
Open
|
201 Jones Rd, Suite 400
|
Waltham
|
MA
|
US
|
02451
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
148626
|
Apr 11th, 2024 12:00AM
|
Tetraphase Pharmaceuticals
|
3.9K
|
16.00
|
Open
|
|
Apr 10th, 2024 11:46PM
|
Apr 11th, 2024 11:23AM
|
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions.
Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
|
Open
|
Antibiotics, Gram-negative antibiotics, multidrug-resistant infections, antibiotic resistance, biopharmaceutical, and bacterial resistance
|
Open
|
480 Arsenal St
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
26006
|
Apr 11th, 2024 12:00AM
|
La Jolla Pharmaceutical Company
|
25K
|
92.00
|
Open
|
|
Apr 10th, 2024 11:46PM
|
Apr 11th, 2024 11:23AM
|
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
|
Open
|
|
Open
|
201 Jones Rd, Suite 400
|
Waltham
|
MA
|
US
|
02451
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
26006
|
Apr 10th, 2024 12:00AM
|
La Jolla Pharmaceutical Company
|
25K
|
91.00
|
Open
|
|
Apr 9th, 2024 11:16PM
|
Apr 10th, 2024 05:31PM
|
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
|
Open
|
|
Open
|
201 Jones Rd, Suite 400
|
Waltham
|
MA
|
US
|
02451
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ljpc
|
148626
|
Apr 10th, 2024 12:00AM
|
Tetraphase Pharmaceuticals
|
3.8K
|
16.00
|
Open
|
|
Apr 9th, 2024 11:16PM
|
Apr 10th, 2024 05:31PM
|
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.
According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions.
Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
|
Open
|
Antibiotics, Gram-negative antibiotics, multidrug-resistant infections, antibiotic resistance, biopharmaceutical, and bacterial resistance
|
Open
|
480 Arsenal St
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
La Jolla Pharmaceutical
|
Health Care
|
Health Care Equipment & Services
|